|
Pulmonary Hypertension, Primary, 1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Adjustment Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.
|
17988634 |
2007 |
|
Cocaine Abuse
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.
|
17988634 |
2007 |
|
Reactive depression
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.
|
17988634 |
2007 |
|
Cocaine-Related Disorders
|
0.300 |
Therapeutic
|
group |
CTD_human |
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.
|
17988634 |
2007 |
|
Transient Situational Disturbance
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.
|
17988634 |
2007 |
|
Depressive disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Furthermore, viral-mediated HDAC5 overexpression in the hippocampus blocked imipramine's ability to reverse depression-like behavior.
|
16501568 |
2006 |
|
Diabetic Nephropathy
|
0.200 |
Biomarker
|
disease |
RGD |
Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy.
|
24717296 |
2014 |
|
Infarction, Middle Cerebral Artery
|
0.200 |
Therapeutic
|
disease |
RGD |
HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury.
|
23480850 |
2013 |
|
Pulmonary Hypertension
|
0.200 |
Biomarker
|
phenotype |
RGD |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Right Ventricular Hypertrophy
|
0.200 |
Biomarker
|
disease |
RGD |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Acute kidney injury
|
0.200 |
Biomarker
|
disease |
RGD |
Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney.
|
21416250 |
2011 |
|
Attention Deficit Disorder
|
0.200 |
Biomarker
|
disease |
RGD |
A comparison of molecular alterations in environmental and genetic rat models of ADHD: a pilot study.
|
18937310 |
2008 |
|
Triglycerides measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
|
23063622 |
2012 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies.
|
19801982 |
2009 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies.
|
19801982 |
2009 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Class I histone deacetylases (HDACs) generally promote cell proliferation and tumorigenesis, whereas class IIA HDACs like HDAC4 and HDAC5 may promote or impede cancer development in a tissue-dependent manner.
|
31052182 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
A comparative microarray analysis demonstrated a genome wide cooperative effect of HDAC5 and LSD1 on cancer-related gene expression. shRNA knockdown and sulforaphane inhibition of HDAC5/LSD1 exhibited similar effects on expression of HDAC5/LSD1 target genes.
|
29633255 |
2018 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Histone deacetylase 5 (HDAC5), as a member of the class IIa family of HDACs, is frequently dysregulated in human malignancies.
|
30066893 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
SMAR1 inhibited Wnt/β-catenin signaling by recruiting Histone deacetylase-5 to β-catenin promoter resulting in reduced cell migration and invasion.
|
29765542 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
On the contrary, HDAC5 knockdown largely decreased the proliferation and invasion and enhanced the apoptosis of A549 cells.
|
30066893 |
2018 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
More importantly, Tbx3 directly interacts with HDAC5 via these motifs, and an HDAC inhibitor blocks Tbx3-mediated cell migration and the downregulation of E-cadherin in HCC.
|
30151243 |
2018 |
|
Liver carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In the present work, we found that the levels of HDAC5 were significantly higher in HCC tissues and cells than in adjacent tissues and normal hepatic cells.
|
29637001 |
2018 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
|
28440397 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
We found that histone deacetylase 5, a highly expressed histone deacetylase in hepatocellular carcinoma, strengthened the migration and invasion of hepatocellular carcinoma cells under hypoxia but not normoxia condition.
|
28653891 |
2017 |